Zetomipzomib
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Mar 7, 2018 (NCT03393013)
Timeline
Indications
Mechanism of action
- Proteasome subunit beta type-8INHIBITOR
PSMB8 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc([C@@H](O)[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1- Mol. weight
- 586.69 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297468 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05781750 | Phase 2 | Nov 3, 2023 | Kezar Life Sciences, Inc. |
| NCT05569759 | Phase 2 | Dec 31, 2022 | Indiana University, Kezar Life Sciences, Inc., University of Pennsylvania |
| NCT04628936 | Phase 2 | Nov 4, 2020 | Kezar Life Sciences, Inc. |
| NCT04033926 | Phase 2 | Aug 31, 2019 | Kezar Life Sciences, Inc. |
| NCT04039477 | Phase 2 | Aug 31, 2019 | Kezar Life Sciences, Inc. |
| NCT03393013 | Phase 1/Phase 2 (Phase 2) | Mar 7, 2018 | Kezar Life Sciences, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kezar Life Sciences, Inc. | For profit | 6 | 6 | 1 | 2018 |
| Indiana University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1